Tokyo, Sept 29, 2009 (JCN Newswire) - Eisai Co., Ltd. announced today that it had submitted an application for additional indication of its proton pump inhibitor PARIET(R) (generic name: rabeprazole sodium) for non-erosive gastro-esophageal reflux disease (GERD) in Japan. The application for this additional indication was originally submitted on March 27, 2006 and was withdrawn in February 2008. However, the application has been recently resubmitted following the completion of additional studies to support data for the new indication.
